The UK perspective on prostate cancer researchProfessor Malcolm Mason, prostate cancer specialist, gives Oncology Times the rundown on some of thedoi:10.1097/01.OTU.0000414830.80007.e3FogartyMaryOncology Times Uk
This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.Latest News Norway Grants Marketing Authorization to Illuccix PSMA-...
Ingrid Stenstadvold Ross, CEO of the Norwegian Cancer Society, said:“The partnership with Cancer Research UK’s Centre for Drug Development marks a milestone for the Norwegian Cancer Society, enabling us to advance the development of groundbr...
Official Fundraiser Team Darts Prostate Cancer UK 45 donations 92% £3,713.39 Donate Snowy Dyson Snowy's PCUK 19 donations 848% £3,604.56 Donate Enid Vincent Enid's Enid Vincents Wingwalk for prostate cancer research! 20 donations 155% £3,108.00 Donate Sally Haines Design...
Medical oncology, genitourinary oncology, renal cell carcinoma, urothelial carcinoma, prostate cancer, testicular cancer, adrenal cancer, GU oncology, immmunotherapy, patient reported outcomes Dr. Mir Mohd Faheem, PhD Council of Scientific & Industrial Research Indian Institute of Integrative Medicine, Jam...
Research11 March 2025 Additional findings in prostate MRI Fabio Porões, Paraskevi Karampa, Thomas Sartoretti, Hugo Najberg, Johannes M. Froehlich, Carolin Reischauer and Harriet C. Thoeny Research11 March 2025 Innovative optimization of greater omentum imaging report and data system for enhanced ri...
Prostate Cancer and Prostatic Diseases, covering all aspects of prostatic diseases, in particular prostate cancer. The journal is of interest to surgeons, oncologists, clinicians, and researchers involved in disease of the prostate.
Diaprost´s research and development is targeting prostate cancer with ambition to revolutionize personalized medicine. The goal is to establish an antibody platform, for bothin vivodiagnostic, to simplify and make the identification/detection of prostate cancer more reliable, as well as for targeted...
Enrollment goal met in trial of Vanquish device for localized prostate cancer By Hannah Clarke February 27th 2025 Data from the VAPOR 2 trial are intended to support a submission to the FDA for 510(k) clearance of the device. Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform...
The results, released Saturday, are encouraging for men who want to avoid treatment-related sexual and incontinence problems, said Dr. Stacy Loeb, a prostate cancer specialist at NYU Langone Health who was not involved in the research.